PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.05%
R&D growth while AXSM reduces spending. John Neff would investigate strategic advantage.
231.77%
G&A change of 231.77% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.69%
Operating expenses growth while AXSM reduces costs. John Neff would investigate differences.
-100.00%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
D&A reduction while AXSM shows 134.54% growth. Joel Greenblatt would examine efficiency.
-127.89%
EBITDA decline while AXSM shows 19.22% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-121.69%
Operating income decline while AXSM shows 21.53% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-17.94%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-139.60%
Pre-tax income decline while AXSM shows 20.60% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-139.60%
Net income decline while AXSM shows 20.69% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-131.82%
EPS decline while AXSM shows 20.78% growth. Joel Greenblatt would examine position.
-131.82%
Diluted EPS decline while AXSM shows 20.78% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.